Liposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17β-estradiol: an innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor α
[en] The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion of drug into liposomes or of drug-in-cyclodextrin-in liposomes (DCL) could have on the molecular and cellular mechanism of drug action is largely unknown. As a proof of concept, we evaluated the impact of 17β-estradiol (E2) included into liposomes or DCL on estrogen receptor (ER)α signaling pathways. Indeed, ERα relays the pleiotropic actions of E2 in physiology and pathophysiology through two major pathways: (1) the genomic/nuclear effects associated to the transcriptional activity of the ERα and (2) the rapid/nongenomic/membrane-initiated steroid signaling (MISS) effects related to the induction of fast signaling pathways occurring when ERα is anchored to the plasma membrane. We evidenced that the inclusion of E2 into liposomes (Lipo-E2) or into DCL (DCL-E2) prevented the activation of the rapid/nongenomic/extranuclear/MISS pathway of ERα, while the activation of the genomic/nuclear pathway was maintained. These results support that Lipo-E2 and DCL-E2 could be a useful tool to delineate the complex molecular mechanisms associated to ERα. In conclusion, this study supports the notion that inclusion of drugs into liposomes or DCL could modify some specific pathways of their molecular and cellular mechanisms of action. These results emphasized that attention should be paid to nano-bio interactions induced by the use of nanovectors in medicine.
Research center :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Gallez, Anne ✱; Université de Liège - ULiège > Cancer-Tumours and development biology
Palazzo, Claudio ✱; Université de Liège > Département de pharmacie > Département de pharmacie
Blacher, Silvia ; Université de Liège - ULiège > Cancer-Tumours and development biology
Noël, Agnès ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Evrard, Brigitte ; Université de Liège - ULiège > Département de pharmacie > Pharmacie galénique
Pequeux, Christel ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Piel, Géraldine ✱; Université de Liège - ULiège > Département de pharmacie > Développement de nanomédicaments
✱ These authors have contributed equally to this work.
Language :
English
Title :
Liposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17β-estradiol: an innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor α
Abot, A., Fontaine, C., Raymond-Letron, I., Flouriot, G., Adlanmerini, M., Buscato, M., Otto, C., Bergès, H., Laurell, H., Gourdy, P., Lenfant, F., Arnal, J.F., The AF-1 activation function of estrogen receptor α is necessary and sufficient for uterine epithelial cell proliferation in vivo. Endocrinology 154:6 (2013), 2222–2233.
Adlanmerini, M., Solinhac, R., Abot, A., Fabre, A., Raymond-Letron, I., Guihot, A.L., Boudou, F., Sautier, L., Vessières, E., Kim, S.H., Lière, P., Fontaine, C., Krust, A., Chambon, P., Katzenellenbogen, J.A., Gourdy, P., Shaul, P.W., Henrion, D., Arnal, J.F., Lenfant, F., Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc. Natl. Acad. Sci. USA 111:2 (2014), E283–E290.
Al-Azayzih, A., et al. Liposomal-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitorIPA-3limits prostate tumor growthin vivo. Nanomedicine 12:5 (2016), 1231–1239.
Al-Jamal, W.T., Kostarelos, K., Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44:10 (2011), 1094–1104.
Arnal, J.F., Gourdy, P., Lenfant, F., In vivo dissection of the estrogen receptor alpha: uncoupling of its physiological effects and medical perspectives. Ann. Endocrinol. (Paris) 74:2 (2013), 82–89.
Arnal, J.F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., Katzenellenbogen, J., Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol. Rev. 1;97:3 (2017), 1045–1087.
Billon-Galés, A., Krust, A., Fontaine, C., Abot, A., Flouriot, G., Toutain, C., Berges, H., Gadeau, A.P., Lenfant, F., Gourdy, P., Chambon, P., Arnal, J.F., Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc. Natl. Acad. Sci. USA 108:32 (2011), 13311–13316.
Bowey, K., Tanguay, J.F., Tabrizian, M., 2-Dioleoyl-sn-glycero-3-phosphocholine-based nanoliposomes as an effective delivery platform for 17beta-estradiol. Eur. J. Pharm. Biopharm. 86:3 (2014), 369–375.
Chen, J., Lu, W.L., Gu, W., Lu, S.S., Chen, Z.P., Cai, B.C., Yang, X.X., Drug-in-cyclodextrin-in-liposomes: a promising delivery system for hydrophobic drugs. Exp. Opin. Drug Deliv. 11:4 (2014), 565–577.
Cipolla, D., Blanchard, J., Gonda, I., Development of liposomal ciprofloxacin to treat lung infections. Pharmaceutics, 8(1), 2016.
Deroo, B.J., Korach, K.S., Estrogen receptors and human disease. J. Clin. Invest. 116:3 (2006), 561–570.
Du, B., Li, Y., Li, X., Youmei, A., Chen, C., Zhang, Z., Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int. J. Pharm. 384:1–2 (2010), 140–147.
Greenwood, A.I., Tristram-Nagle, S., Naglea, J.F., Partial molecular volumes of lipids and cholesterol. Chem. Phys. Lipids 143:1–2 (2006), 1–10.
Haeri, A., Sadeghian, S., Rabbani, S., Anvari, M.S., Erfan, M., Dadashzadeh, S., PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis. J. Microencapsul. 29:1 (2012), 83–94.
Harrington, W.R., Kim, S.H., Funk, C.C., Madak-Erdogan, Z., Schiff, R., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 20:3 (2006), 491–502.
Hugon-Rodin, J., Chabbert-Buffet, N., Bouchard, P., The future of women's contraception: stakes and modalities. Ann. N. Y. Acad. Sci. 1205 (2010), 230–239.
Jain, S.K., Gupta, Y., Jain, A., Bhola, M., Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery. Drug Deliv. 14:6 (2007), 327–335.
Joguparthi, V., Anderson, B.D., Effect of cyclodextrin complexation on the liposome permeability of a model hydrophobic weak Acid. Pharm. Res. 25:11 (2008), 2505–2515.
Kowapradit, J., Apirakaramwong, A., Ngawhirunpat, T., Rojanarata, T., Sajomsang, W., Opanasopit, P., Methylated N-(4-N, N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery. Eur. J. Pharm. Sci. 47:2 (2012), 359–366.
Lechanteur, A., Furst, T., Evrard, B., Delvenne, P., Hubert, P., Piel, G., Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Int. J. Pharm. 483:1–2 (2015), 268–277.
Madak-Erdogan, Z., Kieser, K.J., Kim, S.H., Komm, B., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 22:9 (2008), 2116–2127.
Madak-Erdogan, Z., Kim, S.H., Gong, P., Zhao, Y.C., Zhang, H., Chambliss, K.L., Carlson, K.E., Mayne, C.G., Shaul, P.W., Korach, K.S., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues. Sci. Sign., 9(429), 2016, p. ra53.
Mouritsen, O.G., Life — as a matter of fat. The Emerging Science of Lipidomics, 2005, Springer.
Murata, M., et al. Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. Eur. J. Pharm. Biopharm. 80:2 (2012), 340–346.
Murata, M., Nakano, K., Tahara, K., Tozuka, Y., Takeuchi, H., Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. Eur. J. Pharm. Biopharm. 80:2 (2012), 340–346.
Nardo, L., Re, F., Brioschi, S., Cazzaniga, E., Orlando, A., Minniti, S., Lamperti, M., Gregori, M., Cassina, V., Brogioli, D., Salerno, D., Mantegazza, F., Fluorimetric detection of the earliest events in amyloid beta oligomerization and its inhibition by pharmacologically active liposomes. BBA 1860:4 (2016), 746–756.
Otero-Espinar, F.J., Luzardo-Alvarez, A., Blanco-Mendez, J., Cyclodextrins: more than pharmaceutical excipients. Mini Rev. Med. Chem. 10:8 (2010), 715–725.
Parrish, D., Zhurova, E.A., Kirschbaum, K., Pinkerton, A.A., Experimental charge density study of estrogens: 17beta-estradiol.urea. J. Phys. Chem. B 110:51 (2006), 26442–26447.
Piel, G., Piette, M., Barillaro, V., Castagne, D., Delattre, L., Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics. Int. J. Pharm. 2006:312 (2006), 75–82.
Poulard, C., Treilleux, I., Lavergne, E., Bouchekioua-Bouzaghou, K., Goddard-Léon, S., Chabaud, S., Trédan, O., Corbo, L., Le Romancer, M., Activation of rapid oestrogen signalling in aggressive human breast cancers. EMBO Mol. Med. 4 (2012), 1200–1213.
Schmidt, J., et al. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126:Pt 8 (2003), 1895–1904.
Song, R.X., McPherson, R.A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., Santen, R.J., Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol. Endocrinol. 16 (2002), 116–127.
Soni, V., Kohli, D.V., Jain, S.K., Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J. Drug Targ. 16:1 (2008), 73–78.
Valéra, M.C., Fontaine, C., Dupuis, M., Noirrit-Esclassan, E., Vinel, A., Guillaume, M., Gourdy, P., Lenfant, F., Arnal, J.F., Towards optimization of estrogen receptor modulation in medicine. Pharmacol. Ther. 189 (2018), 123–129.
Varricchio, L., Migliaccio, A., Castoria, G., Yamaguchi, H., de Falco, A., Di Domenico, M., Giovannelli, P., Farrar, W., Appella, E., Auricchio, F., Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide. Mol. Cancer Res. 5 (2007), 1213–1221.
Wang, J., Huang, G., Preparation of itraconazole-loaded liposomes coated by carboxymethyl chitosan and its pharmacokinetics and tissue distribution. Drug Deliv. 18:8 (2011), 631–638.
Yingchoncharoen, P., Kalinowski, D.S., Richardson, D.R., Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol. Rev. 68 (2016), 701–787.
Zhang, Y., Calon, F., Zhu, C., Boado, R.J., Pardridge, W.M., Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther. 14:1 (2003), 1–12.